Scientific commentaries on latest trends and advancements | genOway

Targeted immunotherapy against autoreactive B cells in autoimmune diseases

T-cell engagers in immunotherapies

Our commentaries

Targeted immunotherapy against autoreactive B cells in autoimmune diseases

T-cell engagers in immunotherapies

A radiolabeled VISTA antibody for imaging VISTA expression

hVISTA - antibodies & PET imaging

New CD4-specific minibodies to predict cancer treatment outcomes

CD4 for cancer treatment outcomes

Development of a new antibody-drug conjugate against CD71, INA03, for the treatment of leukemia

TFRC for anti-cancer therapies

HPN328, a new T cell–activating construct for treating solid tumors

CD3ε - T-cell engager assessment

VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response

VISTA - safety and PK profiling

New insights into TNFα aptamers ameliorating inflammation indices in a DTHR humanized TNFα mouse model

Humanized TNFα to study inflammation

BRGSF-HIS: genOway’s mouse model to evaluate the pathogenesis of Staphylococcus aureus Panton-Valentine leukocidin in acute implant-associated osteomyelitis

BRGSF-HIS as model for acute implant-associated osteomyelitis

Development of a new hSIRPα-specific radiotracer for non-invasive PET imaging using genOway’s double humanized genO-hCD47/hSIRPα mouse and genO-MC38-hPD-L1-hCD47-LZ cell line

Targeting the human CD47/SIRPα axis

Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized genO-BRGSF-HIS preclinical model

CRS in genO-BRGSF-HIS

An engineered humanized common light chain mouse model to develop bispecific antibodies

Humanized cLC model - Bispecific antibody development

A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Humanized VISTA mouse & Pharmacokinetics

Targeting myeloid cells in the tumor microenvironment in BRGSF-HIS mice

Myeloid compartment in BRGSF-HIS

Assessing T-cell engagers efficacy in vivo: Versatility of BRGSF-HIS mice

Assess T-cell engager in BRGSF-HIS

CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

Humanized ICP mouse and cell lines

Expression of druggable myeloid targets in the BRGSF-HIS preclinical model

Myeloid compartment in BRGSF-HIS

An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension

Humanized HSA/hFcRn mouse

Functional human myeloid compartment in BRGSF-HIS preclinical model

Myeloid compartment in BRGSF-HIS

A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway

Humanized PD-1/PD-L1 mouse and cell line

Assessing T-cell engagers in vivo: How BRGSF-HIS mice can help

Assess T-cell engager in BRGSF-HIS

Homeostasis of monocytes and lung interstitial macrophages is regulated by collagen domain-binding receptor LAIR1 in vivo

Myeloid compartment in BRGSF-HIS

Challenging the predictability of preclinical models for assessment of T-cell engagers

Assess T-cell engager in BRGSF-HIS

Targeting tumor-associated myeloid cells: The new grail in immuno-oncology?

Myeloid compartment in immuno-oncology

New insights to manage painful neuroma: Study of a nerve graft in rats

Rat models

Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model

T-cell engager CD3

An alternative approach to immunotherapy: A bispecific agonist

Humanized PD-1 & GITR mouse

Relevant preclinical models to test T-cell engagers: The case of CD28

T-cell engager

Tips for choosing the optimal preclinical model: focus on atherosclerosis and LDLR

Rat models

Immunocompromised human serum albumin/human neonatal Fc receptor mouse model: A new xenograft model for efficacy studies of immunotherapies

Therapeutic efficacy and pharmacokinetics

CRISPR-Cas9 effectors facilitate generation of single-sex litters and sex-specific phenotypes

CRISPR/Cas9 technology

The importance of genetic design when choosing your preclinical model: focus on preclinical models for cardiovascular disorders — a case study on BMPR2

Rat models

Immunotherapy efficacy assessment and metastases studies: tHIS model is highly permissive to engraftment

Engraftments in BRGSF-HIS

NOTUM as alternative therapeutic approach to prevent clonal fixation and mutant expansion in patients predisposed to colorectal cancer

Customized mouse model

A human-specific modifier of cortical connectivity and circuit function

Customized mouse model

Predictive in vivo evaluation of immunotherapy efficacy: tHIS is a reliable model

PDX in BRGSF-HIS

Cytokine release syndrome (CRS)

Assess T-cell engager in BRGSF-HIS

When rat models could provide optimized translatability: the case of CD89

Rat models

The importance of genetic design when choosing your preclinical model - A Case Study on GLP-1R

Physiological relevancy in preclinical models

Deciphering high-dose IL-2 toxicity in reconstituted HIS mice

Immunotherapy in BRGSF-HIS

Tumor grafts in preclinical research: Models, models, overall, who is the fittest of them all?

Tumor-graft models

Back to the rat!

Rat models

New doors to potential novel treatments for obesity

Customized mouse model

Uncoupling efficacy from toxicity: a case study on MEDI5752

Bispecific antibodies

Uncoupling toxicity from therapeutic efficacy: a case study on ATOR-1015

Bispecific antibodies

Uncoupling toxicity from therapeutic efficacy: the new challenge of immunotherapies

Assess toxicity with ICP

Degradation tag systems: a good way to SMASh your target (Part 2)

Smash technology

A novel preclinical and translational humanized CD3ε model to study the efficacy of T-cell engagers

T-cell engager

Targeted protein degradation: new promises for “undruggable” diseases (SMASh Part 1)

Smash technology

Define “humanized”: two mouse models helping produce cancer immunotherapies

Humanized mouse models

HSA/hFcRn, a powerful model for your PK/PD studies

Immuno-oncolology models

Part 4: Humanized immune checkpoint mouse models for immuno-oncology studies

Immuno-oncolology models

A Knockin C3-reporter mouse model represents a valuable tool to monitor C3 levels, a biomarker of inflamed versus uninflamed tissues

Customized mouse model

Part 3: BRGSF-HIS, a new human immune system mouse model for immuno-oncology studies

Immuno-oncolology models

Syngeneic mouse models

Customized mouse model

Part 2: BRGSF, a new immunodeficient model for immuno-oncology studies

Immuno-oncolology models

HSC-derived cell fate tracking

Customized mouse model

A VISTA on naive T cell fate

Humanized ICP mouse

Part 1: Toward a better effective preclinical model in immuno-oncology

Immuno-oncolology models

A finely tuned crosstalk between enteric neurons and muscularis macrophages: evidence from a conditional Knockout mouse model developed by genOway

Customized mouse model

Prime Editing: An immature, yet already very exciting new gene editing tool

Prime editing (Cas9-based)

A new Nature report by Bristol-Myers Squibb provides new insights into VISTA biology and design of combination therapies

Humanized ICP in immuno-oncology

FLEx technology and optogenetics: Flipping the switch on gene expression with high spatial and temporal resolution

FLEx technology

6 good reasons to employ our repository Knockout mouse models in your in vivo studies

Eucomm conditional Knockouts

Immune checkpoint inhibitors: A strategy to tackle cancer?

Immuno-oncology models (ICP)

Unexpected genomic rearrangements at targeted loci associated with CRISPR/Cas9-mediated Knockin

CRISPR/Cas9 technology

Improving in vitro models: the coming of age of organoids

Organoids

iPS technology: Four factors that will change the world… some day

iPS technology

CRISPR: A brimming toolbox but no all-in-one

CRISPR technology

No results

Filter

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe